These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 2505272

  • 1. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM, Debruyne FM, Steerenberg PA, de Jong WH, Doesburg W.
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract] [Full Text] [Related]

  • 2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 3. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP, van der Meijden PM, Roos EP, Witjes JA, Steerenberg PA, Doesburg W, Debruyne FM.
    Prog Clin Biol Res; 1992 Feb; 378():59-67. PubMed ID: 1301587
    [No Abstract] [Full Text] [Related]

  • 4. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E, Jauhiainen K, Alfthan O.
    Prog Clin Biol Res; 1989 Feb; 310():271-4. PubMed ID: 2505270
    [No Abstract] [Full Text] [Related]

  • 5. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM, van der Meijden AP, Franssen MP.
    Prog Clin Biol Res; 1989 Feb; 303():435-46. PubMed ID: 2506556
    [No Abstract] [Full Text] [Related]

  • 6. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM, van der Meijden AP, Schreinemachers LM, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg EJ.
    Prog Clin Biol Res; 1988 Feb; 269():511-24. PubMed ID: 3134662
    [No Abstract] [Full Text] [Related]

  • 7. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
    DeBruyne FM, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ.
    Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
    [Abstract] [Full Text] [Related]

  • 8. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA.
    Prog Clin Biol Res; 1989 Mar; 310():275-83. PubMed ID: 2505271
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.
    Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP.
    J Urol; 1995 Mar; 153(3 Pt 2):929-33. PubMed ID: 7853577
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ, Ratliff TL.
    Surg Annu; 1990 Mar; 22():363-78. PubMed ID: 2408170
    [No Abstract] [Full Text] [Related]

  • 15. BCG in the management of superficial bladder cancer.
    Guinan P, Richardson C, Hanna M, Rubenstein M.
    Prog Clin Biol Res; 1989 Mar; 303():447-53. PubMed ID: 2675002
    [Abstract] [Full Text] [Related]

  • 16. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 17. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.
    Witjes JA, vd Meijden AP, Witjes WP, Doesburg W, Schaafsma HE, Debruyne FM.
    Eur J Cancer; 1993 Apr; 29A(12):1672-6. PubMed ID: 8398292
    [Abstract] [Full Text] [Related]

  • 18. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP.
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [Abstract] [Full Text] [Related]

  • 19. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D, von Wietersheim J, Pflüger H, Steiner H, Doehn C, Büttner H, Böhle A, Kausch I.
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [Abstract] [Full Text] [Related]

  • 20. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.